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Background: Ligand-based in silico target fishing can be used to identify the potential interacting target of
bioactive ligands, which is useful for understanding the polypharmacology and safety profile of existing drugs. The
underlying principle of the approach is that known bioactive ligands can be used as reference to predict the
targets for a new compound.
Results: We tested a pipeline enabling large-scale target fishing and drug repositioning, based on simple fingerprint
similarity rankings with data fusion. A large library containing 533 drug relevant targets with 179,807 active ligands
was compiled, where each target was defined by its ligand set. For a given query molecule, its target profile is
generated by similarity searching against the ligand sets assigned to each target, for which individual searches
utilizing multiple reference structures are then fused into a single ranking list representing the potential target
interaction profile of the query compound. The proposed approach was validated by 10-fold cross validation and
two external tests using data from DrugBank and Therapeutic Target Database (TTD). The use of the approach was
further demonstrated with some examples concerning the drug repositioning and drug side-effects prediction. The
promising results suggest that the proposed method is useful for not only finding promiscuous drugs for their new
usages, but also predicting some important toxic liabilities.
Conclusions: With the rapid increasing volume and diversity of data concerning drug related targets and their
ligands, the simple ligand-based target fishing approach would play an important role in assisting future drug
design and discovery.
Keywords: Target fishing, Big data, Molecular fingerprints, Data fusion, Similarity searchingBackground
For many decades, the drug discovery and development
have been directed by the idea of ‘one drug–one target–
one disease’. The paradigm is shifting since many drugs
elicit their therapeutic activities by modulating multiple
targets, as indicated by the polypharmacology [1-3].
However, multi-target interactions are either unknown
or insufficiently understood in most cases, which in-
spired many efforts to predict and characterize drug–
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unless otherwise stated.Use of in silico tools to predict targets of small mole-
cules has drawn more and more attentions in recent
years. These predicted drug targets can be divided into
two types: I) unexploited novel drug targets that can be
used alone or with other drugs in combination chemo-
therapy treatment [3]; II) existing drug targets that pro-
vide new uses and indications for existing drugs [4]. One
of the most prominent examples for drug repositioning
is Sildenafil, which was initially developed for use for
hypertension and angina, and then repositioned for the
treatment of male erectile dysfunction [5]. Other notable
drug repositioning examples include Memantine [6],
Buprenorphine [7], Requip [8,9], Colesevelam [10], and
so on. Numerous computational strategies for targettd. This is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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searchers to deepen the understanding of the bioactive
space of new chemical entities, which provide an efficient
way in designing ligands with favorable pharmacological
and safety profile. Generally, available target fishing ap-
proaches fall into the following two major categories:
1. Target-based Methods
Target-based methods use the information of target pro-
teins, which includes molecular docking, similarity com-
parison of protein sequence or binding pocket, and so
on. For example, INVDOCK [11] and TarFisDock [12]
screen a query small molecule against a panel of prede-
fined target protein structures whereby putative targets
are sorted by docking score [13]. This approach has been
demonstrated to be useful in target identification, and
some of the predicted results have been verified by bio-
assay and crystallographic studies [14,15]. Although sig-
nificant improvements have been made in this area,
there are still practical limitations for target structure-
based approaches, such as unavailable crystal structures
(especially for most trans-membrane proteins), high false
positive rate, the choice of an appropriate scoring func-
tion and high requirement of computational resources
[16]. To circumvent these issues, several target-based
methods relying on the analysis of existing drug-target
interaction data have been developed. For instance, Luo
et al. developed a web server DRAR-CPI to identify drug
repositioning and adverse drug reactions by mining
chemical–protein interactome [17]. Milletti et al. [18]
and Wang et al. [19] predicted polypharmacology by
comparing the structural similarity of binding sites.
Recently, Jacob et al. [20] and Wang et al. [21] con-
structed chemogenomics approaches for qualitatively
predicting ligand-protein interaction that only require
the primary sequence of proteins and the structural fea-
tures of small molecules. These approaches transform
the target fishing problem to a machine learning prob-
lem in the ligand–target space. Though potentially use-
ful, they are sensitive to how a given target protein or
ligand-protein pair is represented by descriptor vectors,
and have a limited application domain defined by their
training set range.
2. Ligand-based Methods
Ligand-based methods simplify the problem to a similarity
searching problem, and only use ligand information to
predict target. Compared with the structure-based ap-
proaches, ligand-based approaches do not rely on the
complete knowledge of ligand-target interaction mecha-
nisms and requires relatively low computational cost.
Based on how a given ligand is represented, these methods
can be divided as 2D fingerprint, molecular shape, pharma-
cophore, and bioactivity spectrum-based, etc.Chemically similar drugs often bind biologically rele-
vant protein targets. To uncover the pharmacological re-
lationships among proteins, Keiser et al. developed a
statistics-based chemoinformatics approach called simi-
larity ensemble approach (SEA) [22], in which each tar-
get was represented solely by the structures of its set of
known ligands. SEA has been applied to quantitatively
identify pharmacological links between targets by the
similarity of the ligands bind to them, expressed as ex-
pectation values (E-value). It was further successfully ap-
plied to large-scale test for drug repurposing [23].
Furthermore, three dimensional (3D) molecular shape
descriptors have turned out to be especially successful in
describing and comparing molecular profiles. Abdul
Hameed et al. developed a novel approach by comparing
shape similarity using program ROCS [24]. In their ap-
proach, target profiles were generated for a given query
molecule by computing the maximal 3D-shape and
chemistry-based similarity to the collection of drugs
assigned to each protein target [25]. Pharmacophore, like
molecular docking, can also be reversely used for in
silico drug target identification. Recently, Liu et al. re-
ported a free web interface PharmMapper that uses
pharmacophore to predict protein targets for small mol-
ecules [26]. This approach automatically performs re-
verse mapping against the deposited pharmacophore
models and outputs the top ranked hits. With the rapid
growth in bioactivity data of small molecules and their
targets, it is possible to employ the information to infer
targets for drugs or bioactive compounds. Cheng et al.
developed an approach named bioactivity profile similar-
ity search (BASS), for associating targets to small mole-
cules by comparing the bioactivity profiles that are
derived from the NCI-60 cell lines [27].
A notable strategy for similarity searching is data fusion
(DF) that utilizes multiple reference structures to search
against a database. A DF process is to combine the infor-
mation provided by multiple independent sensors in order
to make judgments on an event, which was firstly pro-
posed by Peter Willett and his coworkers [28]. Afterwards,
Whittle et al. [29] and Hert et al. [30] used 2D fingerprint
similarity ranking with DF for virtual screening, and dem-
onstrated its effectiveness over conventional similarity
searching in scaffold-hopping searches for structurally di-
verse sets of active molecules [31]. Due to its high search-
ing quality and low computational cost, this approach is
especially fit for the exponential growth in biological data.
Although many advances have been made over the last
decades, drug target prediction is still a very challenging
task as reflected by the low clinical target validation
success rate. The reasons are manifold, yet what poses
the greatest difficulty might be the amount of protein
targets and known active small molecules. For example,
the current version ChEMBL database (version 17) [32]
Table 1 Statistics of the data sets used as reference






Reference library BindingDB 533 179807 246053 [40]
External validation
sets
DrugBank 455 711 7917 [41]
TTD 255 476 1084 [43]
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1,324,941 compounds. Such data collection is so large
and complex that it becomes difficult to process using
traditional molecular modeling process and target-ligand
interaction applications. In this regard, we may consider
the target fishing as a ‘big data’ problem. As defined by
Donglas Laney [33], big data problems mainly have three
aspects of features of data growth, i.e. having increasing
volume (amount of data), velocity (speed of data in and
out), and variety (range of data types and sources). For
target fishing, vast amount of data in various measure-
ments (Ki, Kd, IC50, inhibition rates and so on) are being
generated daily from different sources, with the fast de-
velopment of many high-throughput bioassay systems.
Given the data of these features, we need firstly make a
practical trade-off between the amount of employed data
and the complexity of models. Though under debate, it
has been widely realized that using more data is more
beneficial, because it provides the contextual richness in
data and does not rely on unproven assumptions and
weak correlations. From this aspect, we may argue that
more emphasis should be placed on the data set used
for target fishing, instead of developing algorithms that
are more sophisticated. In this study, we try to address
the target fishing problem from the ‘big data’ perspec-
tive. A large reference ligand library is first established,
with each ligand set to represent a single target. Here,
the DF strategy is adopted to calculate the highest K
similarity scores (or their average value) between the
query and the ligands sets in reference library, using
Tanimoto coefficients (Tc) of ECFP4 fingerprints. The
value of K can be 1, 3, and 5 (denoted as Max, 3NN, and
5NN, respectively), and the average fusion similarity is
a centroid score, which is described in Methods sec-
tion. The target profile of a query chemical is then
provided according to the ranked fusion scores. The
performance of this scheme is tested on two test sets,
and a further validation is made to identify new (off-)
targets and hERG related toxicity. The aim of the
study is to benchmark the target fishing capability by
using a simple ligand-based similarity searching ap-
proach, in the meantime, by employing the available
data as much as possible.
The SEA approach represents a notable recent advance
in identifying protein targets. Here, a locally implemented
SEA approach was run in parallel with our approach for
accuracy assessment, of which the E-value was used to
rank potential targets [22]. We perform this comparison
because both SEA and our approach use active ligand set
to represent target, and use 2D fingerprint based similarity
to obtain the score of a target (The SEA approach can be
considered as a data fusion scheme, where the score of a
target is normalized by the size of its ligand set). It should
be pointed out that SEA requires that the product of theligand set sizes is not less than 100 to guarantee statisti-
cally reliable result [34]. It means that the current SEA is
not appropriate for fishing targets without sufficient refer-
ence ligands. Nevertheless, its result can serve as a control
to see how existing approaches perform on the current
data set.
Results and discussion
Drug related targets (DRTs) and their ligands are favor-
able sources for analyzing target-ligand interaction and
understanding polypharmacological effects of drugs. As
described in Methods section, one reference library con-
taining DRTs with active ligand set and two validation
sets were compiled for this study. Table 1 summarizes
the number of compounds and targets of each set. We
further analyzed the polypharmacological profile of the
ligands in the reference library. As shown in Figure 1,
most active ligands have only one single target, while
there are also significant amount of ligands having two
or three targets. The number of ligands having many tar-
gets is small, and 1,512 ligands have the number of tar-
gets greater than five.
Given a ligand that has m experimentally verified tar-
gets, a target fishing scheme yields n predicted targets
for the ligand (i.e., the top ranked n targets), we used
the following evaluation metrics to measure the per-
formance of the scheme: Precision (PRn), Recall (REn),
F-measure (Fn) [35], and the uninterpolated precision
(PR’) [36]. PR’ is given by the averaged precision values
PRi from the ranking places 1 to m. Here, m for a query
ligand is the number of its interacting targets. The de-
tailed definitions of these terms are provided in the
Methods section.
1. Ten-fold cross-validation
The 10-fold cross validation was performed to determine
the parameter K for the nearest neighbor to fuse and to
evaluate the effectiveness of the fusion strategy when
only a small part of the set was used as reference. In the
validation, the overall reference set was randomly split
into ten parts. For the ligands of each part, their targets
were predicted using the ligands and the targets infor-
mation of the rest 9 parts. The performance achieved for
each part was recorded, and the average PR’ value was
used to evaluate the four fusion schemes as well as SEA
Figure 1 Plot to show the distribution of the number of active ligands against the number of targets per ligand.
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larity among ligand sets, it would not be statistically reli-
able if the ligand sets comprising fewer than ten ligands.
In practice, it is suggested that the product of the set
sizes should be higher than 100 [22,34]. In the case of
target fishing, the set-wise similarity is typically calcu-
lated between a single query ligand and a reference lig-
and set. So in order to perform a comparison, we did
another test for SEA only using the reference targets
whose ligands are equal to or more than 100. Altogether,
292 targets with 173,862 ligands (23,6986 pairs) were
retained as another unique reference set to test SEA per-
formance. As outlined in Table 2, Max scheme performs
a little worse than 3NN and 5NN schemes. Both 3NN
and 5NN show very close results and 3NN slightly out-
perform the others. A possible explanation is that 5NN
includes some ligands that are not very similar to the
query. Instead, the first three neighbors of a query in ref-
erence ligand set may better represent the corresponding
target, and discriminate among other optional targets.
Moreover, it is clear that Centroid score is less effective
than other KNN schemes. In our experiment, SEATable 2 The result (PR’) of 10-folds cross-validation on
the reference set
Max 3NN 5NN Centroid SEA SEA*
Mean 0.927 0.950 0.947 0.228 0.628 0.717
S.E. 0.002 0.002 0.002 0.002 0.001 0.001
*Only the targets containing more than 100 reference ligands were considered
in the validation.
PR’ is given by the averaged precision values PRi from the ranking places 1 to
m. Here, m for a query ligand is the number of its interacting targets.performs a bit worse than KNN fusion. As expected,
KNN strategy is able to determine the target of small
molecules with significant accuracy and robustness in
internal cross validation.
Since the targets here are represented by their refer-
ence ligands, the predictive ability relies on the represen-
tativeness and diversity of reference library. Figure 2
displays a bar plot of the number of active ligands for all
the targets in the reference set. Among all the 533 tar-
gets having more than 10 active ligands, 292 of them
have more than 100 active ligands and 72 of them have
more than 1000 active ligands. These 533 approved drug
targets cover the major members of clinical therapeutic
protein receptors, enzymes and disease related targets.
With the amount of bioassay data growing, our refer-
ence library can be easily extended to incorporate more
ligand-target interaction data. Then, we would like to
know how 3NN behaves on targets with different num-
bers of reference ligands. We studied the PR’ in 10-CV
by grouping the reference targets evenly into 10 bins ac-
cording to the amount of its ligands. The PR’ of a bin is
defined as the average PR’ score for all the targets in that
bin. The yellow line shown in Figure 2 depicts how the
PR’ varies across targets with ascending number of refer-
ence ligands. As the number of reference ligands in-
creases, PR’ increases and the error bar decreases,
suggesting 3NN tends to perform better for the targets
with a large number of reference ligands. Overall, the
PR’ scores range from 0.8 to 0.96, demonstrating that
3NN has excellent accuracy for fishing targets with ad-
equate reference ligands. At the same time, we may also
find that the approach showed a reasonable performance
Figure 2 Plot to show the distribution of average PR’ against the targets with increasing number of reference ligands. PR’ is given by
the averaged precision values PRi from the ranking places 1 to m. Here, m for a query ligand is the number of its interacting targets.
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shown in Figure 2, the majority of targets collected in
our reference set have adequate reference ligands ran-
ging from 102 to 103, which ensured high predictive abil-
ity of the approach.
2. The performance of 3NN with increasing size of
reference Set
With increasing number of active ligands available in
various databases, we want to revisit target prediction in
the context of a ‘big data’. The reference set we collected
contains more than a hundred thousand active ligands
and it will definitely grow in the future. Therefore, we
would like to investigate the performance change of
3NN as more reference compounds become available.
As every target is represented by a set of active ligands,
we created a test set of 2665 ligands by randomly pick-
ing five ligands from each of the 533 targets. The
remaining reference ligands were used as the reference
set. In order to study 3NN on different sizes of reference
sets, a total number of eight reference sets were made
by randomly sampling 0.1%, 1%, 5%, 10%, 20%, 50%, 80%
and 100% from the remaining reference ligands. Then,
we ran 3NN utilizing each of reference sets and record
their PR’ values. The experiment was repeated five times
and the overall result was depicted in Figure 3. When
only 0.1% information is used, the average PR’ is close to
0 with a small SD of 0.2, suggesting that most of the tar-
gets cannot be identified by the small reference set. The
PR’ is gradually increasing as more reference information
involved. When 10% references were used, the average
PR’ is more than 0.6 but the error bar is relatively larger
(SD = 0.44). It suggests that the prediction accuracy of
3NN may reach a high level if the related reference set is
of considerable volume, but the variance of prediction isalso large, which is also the result that would occur in
most cases for similarity-based approaches. When 50%
reference ligands were used, we may find that the PR’
had a notable increase to 0.89 and SD reduced to 0.29,
which indicates that more targets could be identified for
test molecules. It is also worth noticing that the line flat-
tens and the error bar decreases when more than half of
the references were used, which shows that there is only
marginal gain in prediction performance (average PR’) if
the related reference set is of a sufficient large volume.
Finally, by using the total reference set, the average PR’
and SD are 0.96 and 0.18, respectively. The test demon-
strates that the more prior knowledge may not only im-
prove the prediction accuracy of 3NN fusion strategy in
target predicting, but also reduce its prediction variance.
Given a query compound, it is interesting to investi-
gate how similar ligands the reference set contains and
whether the similarity will affect target predicting. For
the test set containing 2665 compounds, we checked the
variation of PR’ versus the similarity of a query to its
closest neighbor in its corresponding reference ligand
set, as shown in Figure 4. On the one side, we may find
the 3NN model always gave a high PR’ value if the query
can find close neighbors. This observation suggests that
a sufficiently large and diverse reference library is im-
portant for the predicting accuracy, which explains why
the target fishing problem should be addressed from a
“big data” perspective. On the other side, we may also
notice that the 3NN model is robust, as the PR’ reaches
0.65 for those have 0.4 ~ 0.5 similarity scores. It means
that the model is still useful when the query can only re-
trieve some moderately similar ligands.
In general, 3NN achieves high PR’ in the internal val-
idation, which is partially attributed to the close ana-
logues that exists in the both test and reference sets. To
Figure 3 Plot to show the change of PR’ with increasing percent of the reference ligands in use.
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tical cases, two external tests are performed and ana-
lyzed in the following section.
3. Predicting targets for approved drugs from drug bank
and TTD
Many drugs from a wide range of therapeutic areas have
more than one interacting targets, and the multiple on-
target and off-target bindings are essential for their efficacyFigure 4 The bar plot showing the variation of PR’ versus the similari
reference ligand set. This analysis is based on the test set containing 266and side effects. For example, the number of reported
interacting targets for the drugs treating central nervous
system disorders is even up to 64 in our validation set. We
compared 3NN and SEA for target identification for these
multi-target drugs. For each test compound, we considered
the top 20 predicted targets, in terms of the metrics includ-
ing PRn, REn, Fn and PR’. The averaged results of the 711
drugs presented in the DrugBank and 476 drugs in TTD
are reported.ty of a query to its closest neighbor in its corresponding
5 query ligands.
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top 20 predictions for the DrugBank and TTD ligands.
Clearly, the 3NN scheme performs better in the valid-
ation, of which all the metrics are consistently higher
than those of SEA. As depicted, the results of the two
approaches show a similar trend except for the following
minor differences: For the 3NN scheme, gradual de-
creasing PRn and increasing REn are observed, and the
changes are more significant when n is small. For SEA,
PRn decreases more quickly, and its value is close to
zero when n is larger than 10. REn of SEA shows a dif-
ferent appearance, where it only exhibits increase when
n is less than 5, and then leveled off. These results
mean that SEA can only identify the “true targets” in a
few top ranked predictions, and further increasing the
number of predictions will not yield more “true tar-
gets”. In contrast, 3NN is able to retrieve more experi-
mentally observed targets as it allows more predictions,
demonstrating its advantage in addressing the poly-
pharmacology of drugs.
Figure 6(A) and 6(B) show the Fn curves of 3NN and
SEA for drugs from DrugBank and TTD, respectively.
There are a few differences between these two validation
sets DrugBank and TTD. TTD mainly contains the
primary targets directly related to the therapeutic actions
of approved drugs, while DrugBank collects more
comprehensive potentials targets. In addition to the tar-
gets that confer the desired pharmacological effect,Figure 5 Comparison of PRn by 3NN and SEA for the drugs from: (A)
SEA for the drugs from: (C) DrugBank set and (D) TTD set.DrugBank also contains other targets including metabol-
ism enzymes, carrier and transporters. These targets
usually account for the side effects or drug-drug interac-
tions. A comparison of these two sets shows that 64%
drugs in TTD also present in Drugbank. Therefore, we
may consider TTD as a subset of DrugBank, in which
TTD only includes pharmacological targets, and Drug-
Bank includes more comprehensive interaction targets.
Further inspection of Figure 6 reveals that the 3NN
for DrugBank displayed a different pattern on these
two sets. As shown in Figure 6(A), the Fn of 3NN
achieves its maximum value for DrugBank when n
equals to 6 (the vertex of the curve). Clearly, we may
find that the Fn curves of 3NN are consistently higher
than SEA, suggesting its higher performance on pre-
dicting drug targets.
From Figure 6(B), we may also notice that 3NN and
SEA show a similar tendency on TTD, of which the Fn
curves rapidly decline when n > 3. It suggests that the
therapeutic targets can be well identified in the top three
predictions, and considering more targets ranked outside
the top three would result in a significant number of
false predictions. However, if one aims to predict non-
therapeutic targets as well, the prediction rank list
should be extended. As shown in Figure 6(A), the de-
cline of 3NN is still slow when n > 6. Another point of
notice is that for both 3NN and SEA the maximum Fn
value obtained on TTD is higher that on DrugBank. ThisDrugBank set and (B) TTD set; Comparison of REn by 3NN and
Figure 6 Comparison of Fn by 3NN and SEA for the drugs from: (A) DrugBank set and (B) TTD set.
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more reliably predicted. One of the possible reasons
is that the therapeutic targets usually form specific
interaction with their corresponding drugs with high
affinities. However, the non-therapeutic targets, e.g.
CYP450s, may exhibit enormous promiscuity, and they
interact with a huge range of structurally unrelated li-
gands. The weak and non-specific interactions may lead
to inferior performance on predicting drugs interacting
with these targets. More details about this test are pro-
vided in Additional file 1: Table S1 and Table S2.
Alternative target fishing methods include 3D similarity
searching methods as well as those based on machine
learning. The 3D similarity searching methods rely on the
generation of active conformations for both references
and queries, which are difficult to obtain for some flexible
compounds and involve high computational cost. For the
machine learning methods, both known active and in-
active molecules should be present to form a training set.
However, the true inactive data are hardly available in
most public databases, thus significantly restricted their
usages in target fishing. In comparison, the 2D similarity
searching methods only require the positive data and the
chemical fingerprints fast to compute, making it an effi-
cient method for large-scale target fishing.
4. Identification of New (Off-) target-drug interactions
From the previous analysis, we may notice that 3NN
DF scheme based on a large reference set is suitable for
the ligands with multiple targets. It is therefore inter-
esting to investigate its performance on identifying the
new and off-targets from the experimentally verified
drug-target associations. To this end, we tested 3NN
using Keiser’s data that were previously used to verify
the prediction of SEA [23]. The first test set includes
within-boundary predictions for 10 GPCR drugs and
cross-boundary predictions for 4 non-GPCR drugs, and
the second set includes 32 drugs with 39 off-targets
associations.
Table 3 shows the 3NN rankings of the new targets for
the drugs. We noticed that 62 out of 65 new drug-targetassociations can be “hit” at the top 20 predictions, and
most of the targets are predicted in top 1 ~ 6. This result
is consistent with the vertex shown in Figure 6(A) that
3NN could achieve a good predictive ability in top 1 ~ 6.
It also means that new (off-) targets could be success-
fully identified in nearly top 1% of the full set of 533 tar-
gets. Only a few experimentally verified target-ligand
interactions were ranked outside of top 20. For example,
the interaction of β1 adrenergic receptor with Prozac
and Paxil was ranked at the 39th and 75th places by
3NN, respectively. These two drugs were predicted to
interact with β adrenergic receptor by SEA, and later ex-
periments revealed that they are medium-potency
blockers of β1 subtype (i.e., Ki = 4.4 μM for Prozac and
10 μM for Paxil). Since our DRT reference set mainly fo-
cuses on strong binders to a specific protein, the low
rankings of the target for these two drugs may be par-
tially attributed to their low binding affinities to the
target, which are close to the threshold for selecting li-
gands in our reference set. Another important feature
of our DRT reference set is it includes more target
members that were categorized according to their se-
quence similarities. Compared with the reference set
of SEA, our DRT reference set specifies the three sub-
types of β adrenergic receptor, hence not requiring a
separate assay for each one. Actually, for Prozac and
Paxil, their interactions with β1 were ranked highest
among the three subtypes, which are consistent with
Keiser’s assay results.
5. hERG toxicity prediction
Off-target interactions are typically related to adverse
drug effects, among which a prominent example is the
interaction of numerous compounds with hERG, a po-
tassium ion channel expressed in the heart and in ner-
vous tissue. In the past decade, a frequent cause of the
withdrawal of the marketed drugs has been the poten-
tially fatal arrhythmia that is induced by a blockage of
hERG channels [37,38]. In this study, we further investi-
gated the hERG-related off-target prediction using the
3NN target fishing scheme. Table 4 list nine approved
Table 3 Target ranking results of the 3NN scheme on the novel drug-target association set of Keiser et al. [23]




Sedalande Neuroleptic αe adrenergic blocker 3
5-HT1D antagonist 1
Dimetholizine Antihistamine; antihypertensive αn adrenergic blocker 5
5-HT1A antagonist 1
D2 antagonist 2
Kalgut Cardiotonic βa adrenergic agonist 1
Fabahistin Antihistamine 5-HT5A antagonist 3
Prantal Anticholinergic; antispasmodic δntichol agonist 1




Doralese Adrenergical blocker; antihypertensive;
antimigraine
D4 antagonist 6
Prozac 5-HT reuptake inhibitor; antidepressant β adrenergic blocker 39
Motilium Antiemetic; peristaltic stimulant αe adrenergic blocker 6
Paxil 5-HT reuptake inhibitor; antidepressant β adrenergic blocker 75
New cross-class
targets
Xenazine αe (transporter) αe adrenergic receptor (GPCR) 6
Rescriptor HIV-1reverse transcriptase (enzyme) H4 receptor (GPCR) 4




RO-25-6981 NMDAR (ion channel) 5-HTT 5
SERT (transporter) 13
D4 receptor (GPCR) 6
noradrenaline transporter(transporter) 13
κoradren receptor (GPCR) 20
Other off-targets Amisulpride Antipsychotic D2 Antagonist 1
Aripiprazole 5-HT1A Agonist D3 Antagonist 1
5-HT2A Antagonist D2 Antagonist 1
Alcohol Deterrent Antiamyloidogenic Agent
Antipsychotic Treatment of Cocaine Dependency
Benperidol Antipsychotic 5-HT2A Antagonist 2
D4 Antagonist 10
Benzoclidine Antihypertensive Anxiolytic M3 Antagonist 2
Bromperidol Antipsychotic 5-HT2A Antagonist 6
Cabergoline Prolactin secretion inhibitor Dopamine Agonist 2
Adrenoceptor (renoceptornist 2
5-HT1D Agonist 1
Captopril ACE Inhibitor Antihypertensive Cardiotonic Leukotriene A4 Hydrolase
Inhibitor
6
Carbacyclin Antithrombotic Prostaglandin 2
Carvedilol Antianginal Antihypertensive Adrenergic (β) Blocker 1
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Table 3 Target ranking results of the 3NN scheme on the novel drug-target association set of Keiser et al. [23]
(Continued)
Enrofloxacin Antibacterial Quinolone DNA gyrase 1
Fluanisone Neuroleptic 5-HT2A Antagonist 8
Hexoprenaline Bronchodilator Adrenergic (β) Agonist 1
Linezolid Antibacterial Oxazolidinone MAO A Inhibitor 2




Melperone Neuroleptic 5-HT2A Antagonist 1
Metergoline Antimigraine Vasodilator Adrenoceptor (renoceptor Vas 2
Naftopidil Prostate Disorders 5-HT1A Antagonist 7
α- adrenergic Blocker 2
Naringenin Antiulcerative Enzyme inhibitor Enzyme
inhibitor (Histidine decarboxylase)
Xanthine Oxidase Inhibitor 16
Nuvenzepine Antiulcerative M2 Antagonist 1
Pimozide Antipsychotic Anticholinergic, Ophthalmic 3
5-HT2A Antagonist 16
Rabeprazole Antisecretory (gastric acid) Antiulcerative H+/K+-ATPase Inhibitor 1
Rispenzepine Antispasmodic M2 Antagonist 1
Tetrabenazine Anxiolytic D1 Antagonist 3
Tetraminol Antihypertensive Vasodilator Adrenoceptor (renoceptorsive 2
Urapidil αr adrenergic Blocker Antihypertensive 5-HT1A Antagonist 2
Cinitapride hygrogen tartrate Antiulcerative Stimulant, Peristaltic 5-HT4 Agonist 1
Lisuride maleate Antiparkinsonian Dopamine Autoreceptor
Agonist Prolactin Secretion Inhibitor
Adrenoceptor (renoceptorlact 1
Methylphenidate Adrenergic Agents Adrenergic Uptake
Inhibitors Central Nervous System Stimulants
Dopamine Agents Dopamine Uptake Inhibitors
Sympathomimetics
M3 Antagonist 3
Pergolide mesylate Antiparkinsonian, Dopamine Agonist 5-HT1D Agonist 2
Adrenoceptor (renoceptorstni 1
Propafenone hydrochloride Antiarrhythmic βntiarrhythm blocker 3
Terbinafine hydrochlorid Antifungal Squalene Epoxidase Inhibitor 1
Urapidil αr adrenergic Blocker Antihypertensive D2 Antagonist 3
Abbreviations: 5-HT Serotonin, D Dopamine receptor, HIV Human Immunodeficiency Virus reverse transcriptase, H Histamine, NMDAR N-methyl-D-aspartate receptor
(glutamate receptor), SERT serotonin transporter, M Muscarinic acetylcholine receptor.
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[37]. For seven of these drugs, their interactions with
hERG were predicted in the top 20 list. For three drugs,
terfenadine, Sparfloxacin, Droperidol, their interactions
with hERG were even ranked at the first place. For com-
parison, the rankings of therapeutic targets of these
drugs were also listed. We notice that all the on-target
interactions of 9 drugs fall in the top 20 list. These re-
sults highlight the usefulness of the 3NN scheme on
identifying both on and off-targets. Particularly, the high
ranking of hERG as a potential interacting target of a
query compound may serve as a hERG toxicity alert for
further safety investigation.Experimental
1. Reference set preparation
While there are many public databases (ChEMBL
[39], BindingDB [40], PubChem, etc.) storing bioactive
small molecules and target information, there are no
special collections for ligands of DRTs. Here, we build
a collection of the active ligands from BindingDB for
FDA-approved drug targets from DrugBank [41]. The
detailed procedures for the data set preparation are as
follows:
(I) DrugBank provides a list of FDA-approved drug
targets, among which all protein sequences of drug tar-
gets of small molecules were downloaded. Sequences of
Table 4 Target ranking results of the 3NN scheme on nine drugs with hERG toxicity
Drug Therapeutic target 3NN ranking (TT) 3NN ranking (hERG)
Astemizole H1 receptor 3 2
Cisapride 5-hydroxytryptamine 2A/3/4 receptor 5 6
Sertindole D2 receptor 1 2
5-hydroxytryptamine 2A/2C/6 receptor 4
α-hydroxytr adrenergic receptor 5-7
terfenadine Histamine H1 receptor 2 1
Potassium voltage-gated channel subfamily H member 2 1
M3 5
Sparfloxacin DNA topoisomerase 4 subunit A 2 1
DNA gyrase subunit A 3
DNA topoisomerase 2α 6
Droperidol D2 dopamine receptor 3 1
α2 adrenergic receptor 5
levomethadyl Acetate μAceta opioid receptor 1 27
Neuronal acetylcholine receptor 3
Lidoflazine Calcium channel 1 21
Terodiline Calcium channel 47 4
Abbreviations: TT Therapeutic target, H Histamine, D Dopamine receptor, M Muscarinic acetylcholine receptor.
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ate a local BLAST database with NCBI blast [42].
(II) The downloaded sequences from DrugBank were
used to perform similarity search against the local
BLAST database, to find drug-target related targets in
BindingDB and to retrieve their interacting ligands.
Using an E-value threshold (1E-50), we obtained target
mapping between BindingDB sequences and drug target
sequences from DrugBank. A protein target of Bin-
dingDB exhibiting high homology with any of the drug
targets was considered as a potential drug target.
(III) The ligands were further filtered to eliminate
those with weak binding affinity to a specific protein.
The threshold for “active” ligand was set as IC50, Ki, Kd
or EC50 < 10 μM, or ΔG <28.53 kJ/mol.
(IV) The above retrieved protein targets were redun-
dant (i.e. there are identical proteins with different
names), and some of them are highly homologous to
each other (e.g. mutants or from different source organ-
isms). To address the issue, we combined the proteins
showing high sequence similarities by another round of
BLAST searches, with a more stringent E-value thresh-
old of 1E-120. All the active ligands of a “combined”
protein target were pooled together. The resulting data-
base contained 725 targets in all.
(V) To ensure every target has a certain amount of lig-
and representatives, we filtered those targets whose ac-
tive ligands were less than or equal to 10. At last, our
curated database covers 533 targets with 179,807 activeligands in total. Approved drugs are used as an inde-
pendent test set for additional validation.
This established chemical reference library is orga-
nized according to DRTs, and each of them is repre-
sented by a set of corresponding active ligands. In our
reference library, the ligand set contains unique ligands
for each target. All the data preparation procedures are
performed with in-house Python scripts. The reference
library is designed to enable further updating by adding
new target-ligand interaction data.
2. Validation sets preparation
The following two datasets were used to test the target
predicting performance of different approaches, including
approved drugs from Therapeutic Target Database (TTD)
[43], and approved drugs from DrugBank 3.0 [41]. These
datasets contains drug or drug-like compounds and their
protein target sequences. For each set, the small molecules
existing in the reference library were firstly removed, and
the sequences were mapped onto DRTs by similarity search-
ing against the local BLAST database mentioned above.
Conclusions
With the rapid advancement of high-throughput screen-
ing technology, the shear amount of bioassay data is so
huge and increasing so fast that many traditional frame-
works encounter difficulties on launching a large cam-
paign of target fishing. The exploration of more efficient
approach in the context of ‘big data’ is needed for the
Figure 7 The flowchart of the ligand-based similarity-ranking scheme with data fusion.
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scheme using 2D fingerprint similarity ranking with a
DF strategy to predict drug-relevant targets based on a
reference library containing 533 targets with 179,807 ac-
tive ligands. This scheme exhibits good performance on
predicting both therapeutic and non-therapeutic targets
for the approved drugs from DrugBank and TTD. It can
also reproduce 62 out of 65 new drug-target associations
identified by SEA, and successfully predict both on-
target and off-target interactions for 9 drugs withdrawn
due to hERG toxicity. Encouraged by the results, we ex-
pect that the proposed scheme will enable large-scale
target fishing, which is useful for both systematically
identifying the new uses of old drugs and exploring the
molecular basis of their adverse events.
Methods
1. Similarity fusion for target fishing
2D fingerprint is one of the most widely used forms to
represent the chemical structure in molecular similarity
searching. Among various fingerprint algorithms, the
extended-connectivity fingerprint (ECFP) is noteworthy
due to its efficiency and the ability to capture highly spe-
cific atomic information [44]. In this study, the ECFP4
fingerprint was calculated by a component (“Molecular
Fingerprints”) implemented in Pipeline Pilot 7.5 [45].
Given a query compound, its similarity score to a target
is represented by a set of reference ligands is obtained
by fusing the pairwise fingerprint-based molecular simi-
larities. The similarity is measured by the Tanimoto coef-
ficient [46,47]. For a given target j with Nj reference
ligands, the following scores are calculated by different
similarity fusion schemes:
(I) KNN score (KSj) is the average similarity of K most
similar ligands of the target j to the query;(II) Max score (MSj) is a special case of KNN when K
equals to 1, which only considers the most similar
ligand of the target j to the query;
(III) Centroid score (CSj) is the average similarity of Nj
ligands of the target j to the query.
Figure 7 outlines the target fishing workflow. The first
step is to elaborately prepare a well-curated reference
library that covers 533 targets represented by their active
ligands as comprehensive as possible. Then, for a given
query compound, 2D fingerprint based similarity search-
ing runs through the entire sets, and the fusion scores of
each target are calculated. Altogether four types of fusion
scores were calculated, which are KSj MSj and CSj. Finally,
for each fusion score, all the 533 targets were ranked in a
descending order, and the top ranked targets were
regarded as potential targets of the query. The predictive
performances of different types of fusion score were com-
pared with a 10-fold cross-validation test, in terms of the
evaluation metrics defined in the next section.
2. Evaluation metrics
The metrics we used are defined below:
PRn ¼ TPnn ð1Þ
REn ¼ TPnm ð2Þ
Fn ¼ 2: PRn
: REn






In this study, PRn (eq. 1) means the fraction of positive
predictions that are “true” (experimentally verified
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tion in the top ranked n targets; REn (eq. 2) means the
fraction of the “true” targets that can be recognized (pre-
dicted as positive). Both PRn and REn are therefore based
on an understanding and measure of a model's ability to
identify true targets. Fn (eq. 3) is the harmonic mean of
PRn and REn, and a higher Fn score means a better per-
formance on discriminating true targets based on an
overall consideration.
The PR’ was introduced by Amini et al. [36] For every
correctly predicted target that appears at the i-th pos-
ition in the top m ranked targets, which corresponds to
the number of true targets of the ligand, the precision
value at that position PRi was calculated. PR’ is given by
the averaged precision values PRi from the ranking
places 1 to m (eq. 4). According to this definition, the
relevant targets that do not appear in the top m ranked
targets receive a precision score of 0. In the end, the av-
eraged values of the PRn, REn, Fn and PR’ for all com-
pounds of validation datasets were reported.
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